NICE Ltd (NICE) Stock Price & How to Invest

NICE Ltd is an Israeli-headquartered enterprise software company listed on Nasdaq and the Tel Aviv Stock Exchange. Its larger Customer Engagement segment offers CXone Mpower, a cloud contact center platform (CCaaS) that handles routing, digital channels, workforce management, quality and analytics for large enterprises, increasingly bundled with AI agents and self-service automation. Its smaller Financial Crime and Compliance segment, NICE Actimize, provides anti-money-laundering, fraud detection and trade surveillance software to banks and financial institutions. Roughly three quarters of revenue is now recurring cloud revenue, and the company also retains a legacy on-premise and public safety business.

The investment picture is a valuation-versus-disruption argument. NICE still grows: total revenue rose ~9.8% year over year in Q1 2026 to ~$769 million, cloud revenue grew ~14.6%, and AI annual recurring revenue rose ~66%. But growth has decelerated from the mid teens toward high single digits, and new CEO Scott Russell is deliberately spending down profitability (2026 operating margin guided to ~25% to 26% versus ~31% in 2025) to fund AI development after the ~$955 million Cognigy acquisition. The market has treated that as a signal that agentic AI threatens the per-seat economics of contact centers, and the stock lost roughly 45% over the past year. What is left is a business at a mid-single-digit EV/EBITDA with ~$1 billion of repurchase capacity and an active sale process for Actimize that has drawn bids near ~$2.5 billion, against a market cap of about ~$5.1 billion.

The central risk is structural: generative AI could compress the number of human agents enterprises staff, and NICE's contact center economics have historically scaled with seats. Growth has already decelerated from the mid teens toward high single digits, and 2026 margin guidance of ~25% to 26% versus ~31% in 2025 means reported profits fall while the company invests. Competition is intensifying from Genesys (which took a combined ~$1.5 billion investment from Salesforce and ServiceNow), Amazon Connect, Five9, Microsoft and Salesforce itself, several of which can bundle contact center AI into broader platforms. Execution sits with a leadership team that is still relatively new, and part of the improved earnings outlook comes from share repurchases rather than operating growth. The Actimize sale is not closed, so both the proceeds and the resulting standalone profile remain uncertain, and as an Israeli-headquartered issuer the company also carries geopolitical and currency exposure.

13 analysts publish price targets on NICE, averaging $125.46 against a $100.65 price as of August 2026, or +24.6%. The published targets run from $100.00 to $170.00, a moderate spread, and the ratings split 8 buy, 7 hold, 0 sell. Over the last six months there have been 0 raises and 8 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NICE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on NICE Ltd. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Cloud migration and CXone Mpower. Cloud revenue reached ~$603 million in Q1 2026, up ~14.6% year over year, and now represents the large majority of total revenue. The most optimistic published target, $170.00, assumes this works close to its best case.

The case against. The central risk is structural: generative AI could compress the number of human agents enterprises staff, and NICE's contact center economics have historically scaled with seats. The most pessimistic target, $100.00, is roughly what NICE is worth if this bites instead.

Read the full bull and bear case on NICE, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see NICE Ltd's investor relations page or your broker.

• Revenue (TTM): ~$3.0B
• Q1 2026 revenue: ~$769M (+9.8% YoY)
• Cloud revenue (Q1 2026): ~$603M (+14.6% YoY)
• 2026 revenue guidance: ~$3.17B-$3.19B (~8% growth)
• Market cap: ~$5.1B
• Trailing P/E: ~10x (forward ~8x)

NICE trades at roughly single-digit earnings multiples and a mid-single-digit EV/EBITDA, unusual for a software company still compounding cloud revenue in the mid teens. That multiple embeds a market view that AI erodes the seat-based model faster than AI products replace it. The counterweight is a net cash balance sheet, about ~$1 billion of remaining repurchase capacity, and an Actimize sale process valued near ~$2.5 billion against a ~$5.1 billion market cap.

If you want NICE exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to NICE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get NICE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (ROBT), which spreads the position across many companies. Or build it into a focused thematic portfolio, so NICE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NICE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

NICE is the rare software name priced like a melting ice cube while still growing cloud revenue in the mid teens, so the whole debate is whether AI is its disruptor or its next product line.

Whether NICE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NICE a buy or a sell?, and where the stock could go from here in the NICE stock forecast.

For income investors, whether NICE pays a dividend and how the payout looks is covered in does NICE pay a dividend? And to weigh NICE against a peer, read the full side-by-side comparisons: NICE vs CRM and NICE vs NOW.